FDA approves polatuzumab vedotin-piiq for previously untreated …
On April 19, 2023, the Food and Drug Administration approved polatuzumab vedotin-piiq (Polivy, Genentech, Inc.) with a rituximab product, cyclophosphamide, doxorubicin, and prednisone (R-CHP) for...
Polatuzumab vedotin as a salvage and bridging treatment in relapsed …
2021年7月1日 · Pola serves as a valuable bridging treatment to CAR T-cell therapy and allogeneic hematopoietic cell transplantation. The antibody-drug conjugate polatuzumab vedotin (pola) has recently been approved in combination with bendamustine and rituximab (pola-BR) for patients with refractory or relapsed (r/r) large B-cell lymphoma (LBCL).
Polatuzumab Vedotin for the Front-Line Treatment of Diffuse …
Polatuzumab vedotin is an antibody-drug conjugate that targets CD79b, a cell surface marker expressed by B cells (Dornan et al., 2009; Genentech Inc., 2020). Accelerated approval was based on the phase II GO29365 study in 80 patients who received polatuzumab vedotin in combination with bendamustine and rituximab (PBR) or bendamustine and ...
Polatuzumab vedotin plus bendamustine and rituximab in …
2022年1月19日 · Polatuzumab vedotin is an antibody–drug conjugate targeting CD79b to deliver a microtubule polymerization inhibitor, monomethyl auristatin E. 12-14 CD79b is a critical component of the B-cell receptor signaling pathway; it is expressed on all normal B cells and on most mature B-cell malignancies, including DLBCL. 15,16 The phase 1b/2 GO29365 ...
Polatuzumab Vedotin in Previously Untreated Diffuse Large B …
2021年12月14日 · We conducted a double-blind, placebo-controlled, international phase 3 trial to evaluate a modified regimen of R-CHOP (pola-R-CHP), in which vincristine was replaced with polatuzumab vedotin, as...
Pola-BR - Macmillan Cancer Support
Pola-BR is used to treat a type of non-Hodgkin lymphoma called diffuse large B-cell lymphoma (DLBCL). It is best to read this information with our general information about chemotherapy, targeted therapy and the type of cancer you have. Pola-BR …
Therapeutic Plasma Exchange and Its Impact on Drug Levels
2017年8月1日 · We will examine both procedure-specific as well as clinical/pharmacologic drug properties to better demonstrate how these factors interact and influence the effects of TPE on drug levels. We also will detail clinical applications for TPE in moderating drug levels. Finally, we will outline future directions for investigation.
Polypharmacy: Evaluating Risks and Deprescribing | AAFP
2019年7月1日 · Polypharmacy, defined as regular use of at least five medications, is common in older adults and younger at-risk populations and increases the risk of adverse medical outcomes. There are several...
Medication Administration Safety - Patient Safety and Quality
With the growing reliance on medication therapy as the primary intervention for most illnesses, patients receiving medication interventions are exposed to potential harm as well as benefits. Benefits are effective management of the illness/disease, slowed progression of the disease, and improved patient outcomes with few if any errors.
Plozasiran, an RNA Interference Agent Targeting APOC3, for Mixed ...
2024年9月12日 · Background: Persons with mixed hyperlipidemia are at risk for atherosclerotic cardiovascular disease due to an elevated non-high-density lipoprotein (HDL) cholesterol level, which is driven by remnant cholesterol in triglyceride-rich lipoproteins. The metabolism and clearance of triglyceride-rich lipoproteins are down-regulated through apolipoprotein C3 (APOC3)-mediated inhibition of ...
跳至内容